Steroid-Refractory Acute GVHD: Predictors and Outcomes

Table 5

Univariate predictors of nonrelapse morality among patients with acute GVHD at 2 years.

Predictor	𝑁=287	HR	95% CI	𝑃
Age (quartile)
≤35	69	Reference	—	—
>35 to ≤45	69	1	0.7–1.7	0.8
>45 to ≤55	83	0.9	0.6–1.5	0.8
>55	66	1.3	0.8–2.1	0.3
Dose of first line
<2 mg	24	0.4	0.2–0.9	0.02
2 mg	250	Reference	—	—
Unknown	13	Reference	—	—
Response to first line
CR/PR	161	0.4	0.3–0.5	<0.001
Other	126	Reference	—	—
Grade and hyper aGVHD
Grade I-II, no hyperacute GVHD	170	Reference	—	—
Grade I-II, hyperacute GVHD	60	1.2	0.8–1.9	0.4
Grade III-IV, no hyperacute GVHD	44	1.9	1.25–3.0	0.003
Grade III-IV, hyperacute GVHD	13	4.3	2.3–7.9	<0.001
Sex mismatch
Yes	73	1.7	1.2–2.4	0.003
No	214	Reference	—	—
Conditioning regimen
Total body irradiation	48	1.7	1.1–2.8	0.025
High dose, No total Body irradiation	158	0.97	0.6–1.4	0.9
Reduced intensity	81	Reference	—	—
Allotype
Matched-related	139	0.6	0.4–0.85	0.004
Matched unrelated	112	Reference	—	—
Antigen mismatch-related	36	Reference	—	—
Cell type
Bone marrow	161	1.1	0.8–1.6	0.5
Peripheral blood	126	Reference	—	—
Diagnosis
Myeloid	163	Reference	—	—
Lymphoid	100	0.9	0.7–1.4	0.9
Multiple myeloma	8	0.6	0.2–2	0.4
Other	4	0.6	0.1–2.5	0.5
Solid	12	0.6	0.2–1.7	0.3
Disease status at transplant
Active disease	188	1.1	0.8–1.5	0.7
No active disease	99	Reference	—	—
Prior chemotherapy regimens
≤2	182	Reference	—	—
>2	105	1.3	0.9–1.8	0.2
CD34 infused (10e6 cells, quartile)
≤3.5	72	Reference	—	—
>3.5 to ≤4.3	68	0.9	0.6–1.4	0.6
>4.3 to ≤5.5	73	0.7	0.5–1.2	0.2
>5.5	70	1.1	0.7–1.8	0.6